Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

Trial Profile

Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.
    • 11 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top